European Medicines Agency approves BioNTech-Pfizer, Moderna vaccines against omicron


The European Medicines Agency has given its authorization for the use of vaccines against the omicron variant of COVID-19 to both Moderna and BioNTech-Pfizer.

The EU’s drug regulator, the European Medicines Agency (EMA), said on Thursday that it had given the green light to two vaccines that target the omicron variant of COVID-19.

The vaccines were developed by the US-German partnership BioNTech-Pfizer and by the US company Moderna.

The vaccines are the first to target the omicron variant BA.1, as well as being effective against the original strain of the virus. Both also produced vaccines against the first iteration of the virus that were approved by the EMA.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: